# Evaluation of Mirtazapine and Folic Acid for Schizophrenia:

> **NCT01263080** · PHASE4 · COMPLETED · sponsor: **Capital Medical University** · enrollment: 333 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** mirtazapine
- **DRUG:** folic acid placebo
- **DRUG:** mirtazapine placebo
- **DRUG:** folic acid

## Key facts

- **NCT ID:** NCT01263080
- **Lead sponsor:** Capital Medical University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-11
- **Primary completion:** 2012-12
- **Final completion:** 2012-12
- **Target enrollment:** 333 (ACTUAL)
- **Last updated:** 2016-08-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01263080

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01263080, "Evaluation of Mirtazapine and Folic Acid for Schizophrenia:". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01263080. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*